Ovarian Cancer Screening Does Not Appear To Reduce Risk Of Ovarian Cancer Death
6/04/2011
In a clinical trial that included nearly 80,000 women, those who received ovarian cancer screening did not have a reduced risk of death from ovarian cancer compared to women who received usual care, but did have an increase in invasive medical procedures and associated harms as a result of being screened, according to a study in the June 8 issue of JAMA, a theme issue on cancer...
Childhood Cancer Survivors At Increased Risk Of Certain Tumors In Middle-Age
6/04/2011
In a study that included nearly 18,000 children who had cancer, with follow-up of about 25 years, the greatest excess risk associated with a subsequent primary neoplasm (a new tumor) at older than age 40 years was for digestive and genitourinary neoplasms (related to the genital or urinary tract organs), according to a study in the June 8 issue of JAMA, a theme issue on cancer...
Rowan T. Chlebowski, M.D., Ph.D., a principal investigator at the Los Angeles Biomedical Research Institute (LA BioMed), provided his assessment of the seeming contradictions between a previous Women's Health Initiative (WHI) study and a new abstract to be presented June 4 at the 2011 American Society of Clinical Oncology. The abstract reports on the National Cancer Institute of Canada MAP...
EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer announced the presentation of clinical data for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients. The data were presented by the principal investigator for the study, Dr. Ursula A...
Vaccine First To Show Improved Survival Rates For Metastatic Melanoma
6/04/2011
For patients with advanced melanoma, which is the most lethal type of skin cancer, the results of a large clinical trial show that a vaccine combined with the immune-boosting drug Interleukin-2 can improve response rate and progression-free survival. The findings of the study were published in the June 2 issue of New England Journal of Medicine...
Medco Partners With MolecularMD On Personalized Medicine Program For Chronic Myeloid Leukemia
6/04/2011
Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. announce the launch of a personalized medicine program for chronic myeloid leukemia (CML) patients. Through this program, Medco will offer patients diagnosed with CML a molecular test known as qRT-PCR (quantitative real-time polymerase chain reaction) BCR-ABL to monitor the disease...
Cornerstone Pharmaceuticals and Wake Forest Baptist Medical Center announced key findings from a Phase I clinical trial of Cornerstone's first-in-class cancer metabolism inhibitor drug, CPI-613 in Acute Myeloid Leukemia (AML)...
Everist Genomics announced updated results from a study of its OncoDefender-CRC assay, a molecular prognostic test for early-stage colorectal cancer patients, will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2011, in Chicago...
Understanding Cancer Energetics
6/04/2011
It's long been known that cancer cells eat a lot of sugar to stay alive. In fact, where normal, noncancerous cells generate energy from using some sugar and a lot of oxygen, cancerous cells use virtually no oxygen and a lot of sugar...
Customizing targeted therapies to each tumor's molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted by The University of Texas MD Anderson Cancer Center...